Vincristine sulfate

For research use only. Not for use in humans.

目录号:S1241 别名: Leurocristine

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate通过与微管蛋白结合而抑制微管聚合,IC50为32 μM。Vincristine sulfate可诱导凋亡。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 734.41 现货
RMB 582.05 现货
RMB 2229.59 现货
RMB 7118.45 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Vincristine sulfate发表文献47篇:

产品安全说明书

Antineoplastic and Immunosuppressive Antibiotics抑制剂选择性比较

生物活性

产品描述 Vincristine sulfate通过与微管蛋白结合而抑制微管聚合,IC50为32 μM。Vincristine sulfate可诱导凋亡。
靶点
Microtubules [1]
(Cell-free assay)
32 μM
体外研究

Vincristine抑制微管蛋白二聚体聚合亚单位,抑制它们的聚合作用,Ki为85 nM。[1]在低浓度时,Vincristine抑制纺锤体,使染色体分离失败,进而导致中期停滞,并抑制有丝分裂。在较高浓度时,Vincristine可能干扰且诱导全部微管解聚。[2] Vincristine 诱导肿瘤细胞凋亡,且抑制SH-SY5Y细胞增殖,IC50为0.1 µM。Vincristine诱导有丝分裂停滞,促进caspase-3和-9及cyclin B的表达,但降低cyclin D的表达。[3] Vincristine通过干扰微管功能而诱导神经毒性形成,这会导致轴突运输堵塞,从而导致轴突变性。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 M2PsXWNmdGxiVnnhZoltcXS7IFHzd4F6 NUO1fHl2OC1yLkWg{txO NWW5SGFPOjRiaB?= M1zIVoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MUGyOVY3Ozd4OR?=
HepG2-HBV1.1 Mk\YRZBweHSxc3nzJGF{e2G7 NFOxfXkxNTBwNTFOwG0> NIOw[o0zPCCq MV;pcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 M1HzTFI2PjZ|N{[5
HepG2.2.15 MlvPSpVv[3Srb36gRZN{[Xl? NV3BO4lkOC5zIN88US=> M1vjN|I1KGh? NUSwS5hHeHKxbX;0[ZMhcGWyYYTpeIl{KEJidnnyeZMheHKxdHXpckBmgHC{ZYPzbY9v M4jMR|I2PjZ|N{[5
HepG2-HBV1.1 M2jzT2Z2dmO2aX;uJGF{e2G7 MWCwMlEh|ryP MV6yOEBp NFLVU2Nxem:vb4Tld{Bp\XCjdHn0bZMhSiC4aYL1d{Bxem:2ZXnuJIV5eHKnc4Ppc44> NGm4cZgzPTZ4M{e2PS=>
HepG2-HBV1.1 NX7aeI1xTnWwY4Tpc44hSXO|YYm= NFX4NogxNjFizszN MXG0PEBp NUDFXI46eHKxbX;0[ZMh[2WubDDlfINz\XSrb36gc4YhcGWyYYTpeIl{KEJidnnyeZMhdnWlbHXvZ4Fxe2mmczDpcpN1\WGmIH;mJIhmeGG2aYTpd{BDKH[rcoXzJGRidmVicHHyeIlkdGW| NHq4V3kzPTZ4M{e2PS=>
HepG2-HBV1.1 NFrWfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDBbXJbOC5zIN88US=> MWWxMVUh\A>? M1fJPYlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJJRqdWViZHXw[Y5l\W62bIm= NVrWblJiOjV4NkO3Olk>
HepG2-HBV1.1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYixUnJwOC5zIN88US=> NFf3V|YyNTViZB?= MkXqbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36geIlu\SCmZYDlcoRmdnSueR?= MmnmNlU3PjN5Nkm=
HepG2-HBV1.1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUe1dpJYOC5zIN88US=> NYDMfGF[OTJvN{KgbC=> NX\HdFBbcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCVLYDoZZNm M1fqeVI2PjZ|N{[5
HepG2-HBV1.1 NWfwSYs{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGwMlEh|ryP MnKwNVIuPzJiaB?= NEiwWGZqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KFNvcHjhd4U> MnvFNlU3PjN5Nkm=
Raji Mo\BSpVv[3Srb36gRZN{[Xl? Mn;TNE42yqEQvF2= NWXlTFhKPzJiaB?= MnS4ZYJwdGm|aHXzJIF2fG:yaHHnfeKh MmXLNlU1PDZ|N{e=
SK-MEL-28  NFL3flRHfW6ldHnvckBCe3OjeR?= MmjMN|Ahdk1? M3jGeFYhcA>? MlnQbY5lfWOnczDHNwKBm01iY3XscE1kgWOuZTDhdpJme3R? NEm5b4IzPTNzM{CxNC=>
H157 NVrYUFRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHyV5FKSzVyPUGuNFMhyrFiMD6wOEBucXV{TR?= MYmyOVI2PzlzMR?=
Jurkat MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjyNU0{KG6P MX[0POKhcA>? NFvlepdFVVOR NWLWUpQx\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>? M2nyO|I2OTV4MUS2
CEM M2LkRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jvfVEuOyCwTR?= NIDZUWc1QMLiaB?= NXTJUGpLTE2VTx?= NXH6OVhv\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>? Mn;INlUyPTZzNE[=
P12 NVPKV5p6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[xMVMhdk1? MmHMOFjDqGh? MXTEUXNQ NEHuUnZl\WO{ZXHz[ZMhfmmjYnzlJINmdGxiboXtZoVzeyCmb4PlJIRmeGWwZHXueIx6 MWGyOVE2PjF2Nh?=
KB NUHlOFJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwMEC0PUDDuSByLkCwNFEh|ryP MnTJNlUxPTh3Mk[=
KBv200 (ABCB1) NHK4OnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLEN3JKSzVyPUCuN|Q3OiEEsTCwMlAxPjZizszN MWqyOVA2QDV{Nh?=
SUDHL6  MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\2RVHjiIoQvF2= M4LJXlQ5Nzd{IHi= NWrNfFFkcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? NGm2O|QzPDl4MU[wOC=>
SUDHL6  MnnJSpVv[3Srb36gRZN{[Xl? MVix5qCK|ryP NXP6S41tPzJiaB?= NFLkSY9qdmS3Y3XzJJNq\26rZnnjZY51KGGyb4D0c5Rq[yCvb4LwbI9td2e7IHPoZY5o\XNiY3;0doV{fGWmIIfpeIghSkOOMUHBJJNqWk6D MVmyOFk3OTZyNB?=
HCT-116 M{[4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorCS2k2OD13IH7N MnLCNlQ6Ojd6NUe=
SKNBe2C M4DOd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYD5V5hYUUN3ME2zNk45yrF2LkCgcm0> MWKyOFkzOTl{MB?=
IGNR91 M4flN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7RTWM2OD1{ND6zxtEyNjdibl2= MnPGNlQ6OjF7MkC=
SKNAS NHrjTZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTIdmw2UUN3ME2xMlXDuTBwMjDuUS=> NWfwOpNuOjR7MkG5NlA>
LAN1 NYXlV5JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJwM9MxNE4zKG6P Mk\HNlQ6OjF7MkC=
SHSY5Y NIrBdGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrnXFZOUUN3ME24MlLDuTBwNjDuUS=> MX[yOFkzOTl{MB?=
A549-WT MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrtN3lKSzVyPUG5MlQ{PyEEsTCwMlU6PCBibl2= NVzyPVI5OjR6NUi4Nlc>
A549-R Mo\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3j[lFKSzVyPUGyMlE4QCEEsTCwMlM{OyBibl2= NELwN|czPDh3OEiyOy=>
MCF-7-WT MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEW1Z5NKSzVyPUG3Mlc2OiEEsTCwMlIyQCBibl2= NVLy[XdOOjR6NUi4Nlc>
MCF-7-R MkfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4O3cmlEPTB;NT61N|khyrFiMD6xOFQhKG6P NHrGN2wzPDh3OEiyOy=>
A549-R MYPDfZRwfG:6aXPpeJkhSXO|YYm= MlXRTWM2OD1zMj6xO|ghyrFiMD6zN|Mhdk1? MoDWNlQ5PTh6Mke=
MCF-7-R NEH1WZpEgXSxdH;4bYNqfHliQYPzZZk> NX;K[oN3UUN3ME21MlU{QSEEsTCwMlE1PCCwTR?= MWOyOFg2QDh{Nx?=
SW620 NUHFPWRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTdwOECgxtEhOC5yODDuUS=> NX30fZN2OjR5Mk[3N|k>
SW620/AD300 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7DXIx{UUN3ME25NFkvPjBiwsGgPE46OSCwTR?= MUWyOFczPjd|OR?=
HEK293/pcDNA3.1 MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV76eZBbUUN3ME2xMlQ2KMLzIECuNlAhdk1? NWDHV5R5OjR5Mk[3N|k>
HEK293/ABCC1 NX7EcJZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfpTWM2OD1zOT6yPUDDuSB{LkC4JI5O MVKyOFczPjd|OR?=
TCC NUnXZlJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTZXVgzPCCq NED2elNKSzVyPUewJI5O MmTWNlQ4OTZ7NES=
TCC MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrzPWJnPDhiaB?= NGHQVI5KSzVyPUWwJI5O NXe0SGxZOjR5MU[5OFQ>
HepG2/ADM NVq0cFFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrVTWM2OD1{Lke4OlPDuTBwMkO3NUDPxE1? M{i3UlI1PzB2NUW2
HepG2 NFT5VnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnmPFBQUUN3ME2wMlAyOTYEsUCuNFAyPyEQvF2= MYKyOFcxPDV3Nh?=
MCF-7/ADR MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnRTWM2OD12LkS4NlbDuTBwMkC3NEDPxE1? MXqyOFcxPDV3Nh?=
MCF-7 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXP1WmFYUUN3ME2wMlAyPToEsUCuNFA3OiEQvF2= M1\PZlI1PzB2NUW2
A-172  NVfoPZNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYm0W2lvOC5zwrFOwG0> NYT5RoJEOjRxN{KgbC=> M3exRYlvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWg[IVx\W6mZX70cJk> NVyyfIFYOjR3M{CyN|U>
U-251MG NYO1[Jl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\4NE4yyqEQvF2= NH;LS|AzPC95MjDo MmjPbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> M1\sXVI1PTNyMkO1
DLD-1 MkGySpVv[3Srb36gRZN{[Xl? NVPReoNlOTByIH7N MWC0PEBp Ml60dJJwdW:2ZYOgVnVPYDNiZHXt[ZRpgWyjdHnvcuKh MW[yOFQxOzR3Mx?=
CCD18Co M4XnXGZ2dmO2aX;uJGF{e2G7 MYCxNFAhdk1? MXS0PEBp NVnmVpdmeHKxbX;0[ZMhWlWQWEOg[IVu\XSqeXzheIlwdsLi MUKyOFQxOzR3Mx?=
DLD-1 MlPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LSfFAuOTByMDDuUS=> MXG0PEBp MYPpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MmjsNlQ1ODN2NUO=
CCD18Co MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLXTIUxNTFyMECgcm0> NIHWcYM1QCCq MWXpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MnG2NlQ1ODN2NUO=
HepG2 M33ae2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHlOHVIOjRiaB?= M4HEPGlEPTB;NUKuOgKBkc7:TR?= NFruUpgzPDN2MU[4PC=>
HEK293/pcDNA3.1 MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwMEC0xtExNjByMEOg{txO NULmRWRUOjR{OES3PFM>
HEK293/MRP1 NWr6WJJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTwTWM2OD1yLkC1OeKyOC5yMUKwJO69VQ>? NYLaTWNoOjR{OES3PFM>
Ramos MXXBdI9xfG:|aYOgRZN{[Xl? MVKy5qCK|ryP NV7xdXdNPDhiaB?= MmnZbY5lfWOnczCzOE43LcLzMT65NkUh[XCxcITvd4l{ MXeyOFI2PjR7MR?=
NCI-H1299/pcDNA3 NEDiN3BE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFPl[m8xNTJyIH7N NWPMVnhnQTZiaB?= NEfVS|ZqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NIW4dIUzPDF5N{CxNi=>
H1299/ICAM-3 MoLIR4VtdCCYaXHibYxqfHliQYPzZZk> MmC5NE0zOCCwTR?= Ml:5PVYhcA>? NUKyUmIzcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NIXXNYMzPDF5N{CxNi=>
NCI-H1299/pcDNA3 MYDGeY5kfGmxbjDBd5NigQ>? Mn3QNU82NzFyL{KwxsBvVQ>? MYS5OkBp NYPye2dFcW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmey1|LDC4MEA6NCCjbnSgVGFTWA>? NH;s[Y0zPDF5N{CxNi=>
H1299/ICAM-3 NED0VnZHfW6ldHnvckBCe3OjeR?= NI\vUIkyNzVxMUCvNlDDqG6P M1nrRVk3KGh? NUDLZXltcW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmey1|LDC4MEA6NCCjbnSgVGFTWA>? NW\seppoOjRzN{ewNVI>
W1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnX4TWM2OD1yLkCwN|Ih|ryP MoTNNlQyPDBzN{[=
W1VR Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPBSGh[UUN3ME2wMlA2PiEQvF2= M4XPTlI1OTRyMUe2
K562 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHiTWM2OD1yLkCzNkDDuSByLkCwNUAh|ryP M3LyOlI1OTN3OUO3
K562/ADR MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPpSXBSUUN3ME2zMlI3OSEEsTCwMlQyOiEQvF2= MYSyOFE{PTl|Nx?=
K562 M1\0SGFxd3C2b4Ppd{BCe3OjeR?= MVSwMlMh|ryP NYK0[WFXOjRiaB?= NEPKdolqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 NXHyc5RDOjRzM{W5N|c>
K562/ADR MUTBdI9xfG:|aYOgRZN{[Xl? NWDZOlM{OyEQvF2= MYSyOEBp NH7iUWhqdmS3Y3XzJIFxd3C2b4Ppdy=> NWrVXHlIOjRzM{W5N|c>
A549 NXSzdGp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PH[WlEPTB;MD6xNEDDuSByLkCzJO69VQ>? NFyyXXEzOzl5MUC3OS=>
K562 NIfscG5E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWewUHZ5Oy55NfMAl|YxyqCwTR?= MnnlO|LDqGkEoB?= NXjR[YFJcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= Mkf3NlM5Pzd{MkO=
lucena MkHjR4VtdCCYaXHibYxqfHliQYPzZZk> NE\LeG0{Njd34pETOlDDqG6P Ml36O|LDqGkEoB?= M3;Ye45wKGWoZnXjeC=> MViyN|g4PzJ{Mx?=
FEPS M4XzXGNmdGxiVnnhZoltcXS7IFHzd4F6 M{PsV|MvPzYkgKO2NOKhdk1? M3\uPFczyqCqwrC= MX\uc{Bm\m[nY4S= NEjze2YzOzh5N{KyNy=>
A2780 Mnn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTNwNTDtUS=> NVHXSlZtOjN6MkmyNFM>
ACHN NXf1V3F4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfMOIFKSzVyPECuNUBuVQ>? M3i0clI{QDJ7MkCz
U-937 M4Sxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRDN2IH7N NUHKWW51OjN6MkmyNFM>
Jurkat MkDMRZBweHSxc3nzJGF{e2G7 MYK1xsDPxGdxbX|CpC=> NFTJdJkzPCCq NEi0e4RqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 MnrHNlM5OTB2MEm=
Jurkat MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXwemE2yqEQvHevcYzDqA>? NVHmSI5pOjRiaB?= MVPhdpJme3RiSoXyb4F1KGOnbHzzJIlvKEd{L12gdIhie2V? NV3YR4hROjN6MUC0NFk>
Hep-2 M3r5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;lRVNKSzVyPUCuNFTDuTBwMEGg{txO NVm3b5N{OjN5OEC0NlQ>
Hep-2/v NVHKNlFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLHTWM2OD1zLklCtVAvOjBizszN M4nXbFI{PzhyNEK0
SGC-7901 NYnIN|hrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHlPZVVOC1zMDFOwIcwdWx? NHnGPG8zPC92OD:3NkBp MUDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= NX3xXHd3OjN5NEO1O|I>
SGC-7901/VCR MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvZV4gxNTFyIN88[{9udA>? NIr5TpozPC92OD:3NkBp MlfrbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy M{OzOlI{PzR|NUey
SGC-7901 MkjMRZBweHSxc3nzJGF{e2G7 M3ToTIlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? MoK1NlM4PDN3N{K=
SGC-7901/VCR MojlRZBweHSxc3nzJGF{e2G7 MnvqbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? MXKyN|c1OzV5Mh?=
KB-3-1 NVrPSHJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvwTWM2OD1zLk[2JOKyKDBwMU[yJO69VQ>? MorONlM3PzN2NEW=
KB-C2 MmD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2T5b2lEPTB;MkCyMlU3KMLzIESyMlQ5OSEQvF2= Mn;hNlM3PzN2NEW=
KB-3-1 NI[3e3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLaUmhqUUN3ME2xMlI3KMLzIECuNFI4KM7:TR?= M2X1W|I{Pjd|NES1
KB-V1 MnjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLETWM2OD1{MEiuPFUhyrFiMkCuOEDPxE1? MnH0NlM3PzN2NEW=
HEK293/pcDNA3.1 NHHhephIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDQTWM2OD1{ND6xJOKyKDBwMkC0JO69VQ>? NUfSXWNzOjN4N{O0OFU>
HEK293/ABCB1 Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLTPFVKSzVyPUO1NVIvQCEEsTCzO|gvOzlzIN88US=> NYLSPIxJOjN4N{O0OFU>
A549/EGFP  MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUiwMlAyNTFyMECg{txO NIrhUG9KSzVyPUi2MlchyrFiMkmuNUDPxE1? M4jVTFI{PjN2Mkiy
A549/Slug M1Lib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvrNE4xOS1zMECwJO69VQ>? NVfLNolxUUN3ME25MlchyrFiMz6xJO69VQ>? M3;pT|I{PjN2Mkiy
JFCR39  MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzJdGdZOSEEtV2= Mn;3NlQhcA>? Ml;vSG1UVw>? NX3tZpREdWG{a3XkcJkhcW6lcnXhd4V{KHSqZTDueY1j\XJib3[gS|IwVSCyaHHz[UBk\Wyucx?= NIq1SmwzOzV7OEK3Oi=>
A549 NWfPVWxRTnWwY4Tpc44hSXO|YYm= Mn\KNVAxKG6P M3nvUFE3KGh? NEjlOZRFVVOR MXfs[YFleyC2bzDhJIxwe3Nib3[gcYlkem:2dXL1cIV{ MoPuNlM2QTh{N{[=
SGC7901 NWX3WIlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3mRZVKSzVyPUGuNlbjiIoEsfMAjVAvOTFizsznM41t M1;wTVI{PTZ2NEiy
SGC7901/LV-NC NELobY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfZSpRKSzVyPUGuO|fjiIoEsfMAjVAvOTZizsznM41t MYKyN|U3PDR6Mh?=
SGC7901/LV-SGO1 NWTMV21[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPsTWM2OD12LkO25qCKyrIkgJmwMlM4KM7:Zz;tcC=> NFXT[ZgzOzV4NES4Ni=>
SGC7901/VCR Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\rUJBEUUN3M{2yNE42O+LCidMx5qCKOS57NjFOwIcwdWx? NULoR|N2OjN3NkS0PFI>
SGC7901/VCR-NC NXzJSppUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHhTWM2OD1zOT64OwKBkcLz4pEJNk4xOSEQvHevcYw> NYfNSGJqOjN3NkS0PFI>
SGC7901/VCR-si-SGO1 M4ex[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk[1TWM2OD14LkG45qCKyrIkgJmxMlA{KM7:Zz;tcC=> M1fBbFI{PTZ2NEiy
SGC7901/ADR MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT3WVRnUUN3ME23Mlg26oDLwsJihKkxNjZ2IN88[{9udA>? M4D1dlI{PTZ2NEiy
SGC7901/ADR-NC MlL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHmeVZKSzVyPUiuPVPjiIoEsfMAjVAvPjhizsznM41t MljtNlM2PjR2OEK=
SGC7901/ADR-si-SGO1 NF7LS|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\FdWlEPTB;Mz60OwKBkcLz4pEJNE4zQSEQvHevcYw> M1uyc|I{PTZ2NEiy
SH-SY5Y  MoTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4no[|AvODBzLUGwJO69VQ>? MkHlNlQhcA>? M4jYb2lEPTB;MD6xNVPDuTBwMEGyJO69VQ>? NXTQfHRSOjNzMkmwOlU>
SH-SY5Y  NX7IflEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYC4XGR{OC5yMEGtNVAh|ryP NVm3NWpRPDhiaB?= MU\JR|UxRTBwMEe4xtExNjByOTFOwG0> NXPPO4hJOjNzMkmwOlU>
SH-SY5Y  NFW2UG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PIfVAvODBzLUGwJO69VQ>? NETM[VY4OiCq Mn7YTWM2OD1yLkC1NeKyOC5yMEig{txO NUnZRVFEOjNzMkmwOlU>
SH-SY5Y MVnBdI9xfG:|aYOgRZN{[Xl? NHL2doQxNjFizszN NFPGbpkxNTJ2IHi= NGfP[FRqdmS3Y3XzJIFxd3C2b4Ppd{Bw\iCVSD3TXVV[KGOnbHzzJIZwdGyxd3nu[{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCC2aHWgS|IwVSCyaHHz[S=> NGqzTJgzOzF{OUC2OS=>
SH-SY5Y NXHMTmlXSXCxcITvd4l{KEG|c3H5 NHu5cWQxNjFizszN MUWwMVI1KGh? M17GOIlv\HWlZYOgcYl1d3SrYzDhdpJme3UEoB?= NYDMfpBYOjNzMkmwOlU>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
MPM2 / Cyclin B1 / Cdc25c / p-Cdc2 / Cdc2 / Aurora B / p-H3 / p-PLK1; 

PubMed: 26156322     


MOLT-4 Cells were treated with vincristine (0.3, 1, and 3 nM) alone or co-treated with SAHA (500 nM) for 24 h. Then, total cell lysates were obtained to evaluate the G2/M phase regulatory protein expression and the tubulin acetylation. Data are expressed as mean values ± SD of at least three separate determinations. S SAHA, V vincristine

26156322
Growth inhibition assay
Cell viability ; 

PubMed: 26156322     


MOLT-4 cells were treated with various concentrations of vincristine for 24 and 48 h, respectively.  Cell viability was measured by MTT assay.

26156322
体内研究 Vincristine 按3 mg/kg剂量单独腹腔注射给药携带双侧皮下移植瘤RH12或RH18的小鼠,平均生长延迟120天和52天以上,且再植指数分别为0.06%和5%。[5] Vincristine 处理小鼠,通过宿主细胞介导的血管效应及直接的微管蛋白介导的的细胞毒性作用而对皮下结肠38肿瘤起作用。Vincristine (5 mg/kg) 降低肿瘤血流量,降低近75%。[6]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[1]
- 合并
  • Cell lines: B16 黑色素瘤细胞
  • Concentrations: 10 nM
  • Incubation Time: 3 天
  • Method: 细胞按5 × 104 cells/mL的浓度接种在含2 mL培养基的35-mm 实验板上,在37°C下 含5% CO2 和95% 空气 的环境下生长24小时。然后使用有或无10 nM药物的新鲜培养基更换原来的培养基,继续增殖3天。使用胰蛋白酶和EDTA将细胞分离后,每天使用库氏计数器完成细胞计数
    (Only for Reference)
动物实验:[5]
- 合并
  • Animal Models: 携带人类横纹肌肉瘤移植瘤Rh12的鼠
  • Dosages: 3 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
Saline
30 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 923.04
化学式

C46H58N4O14S

CAS号 2068-78-2
储存条件 粉状
溶于溶剂
别名 Leurocristine

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03981510 Recruiting Diagnostic Test: 3D-Transit Constipation|Childhood Acute Lymphoblastic Leukemia|Neurofibromatosis 1|Chronic Constipation With Overflow University of Aarhus June 2019 Not Applicable

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?

  • 回答:

    According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Tags: 购买Vincristine sulfate | Vincristine sulfate供应商 | 采购Vincristine sulfate | Vincristine sulfate价格 | Vincristine sulfate生产 | 订购Vincristine sulfate | Vincristine sulfate代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID